Cargando…

Immunotherapy of Cancer: Reprogramming Tumor-Immune Crosstalk

The advancement of cancer immunotherapy faces barriers which limit its efficacy. These include weak immunogenicity of the tumor, as well as immunosuppressive mechanisms which prevent effective antitumor immune responses. Recent studies suggest that aberrant expression of cancer testis antigens (CTAs...

Descripción completa

Detalles Bibliográficos
Autores principales:	Payne, Kyle K., Toor, Amir A., Wang, Xiang-Yang, Manjili, Masoud H.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi Publishing Corporation 2012
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3477552/ https://www.ncbi.nlm.nih.gov/pubmed/23097673 http://dx.doi.org/10.1155/2012/760965

Ejemplares similares

Cancer immunotherapy: Re-programming cells of the innate and adaptive immune systems
por: Manjili, Masoud H., et al.
Publicado: (2012)

Tumor-reactive immune cells protect against metastatic tumor and induce immunoediting of indolent but not quiescent tumor cells
por: Payne, Kyle K., et al.
Publicado: (2016)

IFN-γ Rα Is a Key Determinant of CD8+ T Cell-Mediated Tumor Elimination or Tumor Escape and Relapse in FVB Mouse
por: Kmieciak, Maciej, et al.
Publicado: (2013)

The premise of personalized immunotherapy for cancer dormancy: Cancer dormancy vaccines
por: Manjili, Masoud H.
Publicado: (2020)

Engineering Nanoparticles to Reprogram the Tumor Immune Microenvironment for Improved Cancer Immunotherapy
por: Saeed, Madiha, et al.
Publicado: (2019)

Metabolic reprogramming and crosstalk of cancer-related fibroblasts and immune cells in the tumor microenvironment
por: Zhu, Yifei, et al.
Publicado: (2022)

Tumor escape and progression of HER-2/neu negative breast cancer under immune pressure
por: Kmieciak, Maciej, et al.
Publicado: (2011)

Peripheral blood mononuclear cells of breast cancer patients can be reprogrammed to enhance anti-HER-2/neu reactivity and overcome myeloid-derived suppressor cells
por: Payne, Kyle K, et al.
Publicado: (2013)

From Reductionistic Approach to Systems Immunology Approach for the Understanding of Tumor Microenvironment
por: Koelsch, Nicholas, et al.
Publicado: (2023)

CAF-immune cell crosstalk and its impact in immunotherapy
por: Maia, Ana, et al.
Publicado: (2022)

HLA-DR expression on myeloid cells is a potential prognostic factor in patients with high-risk neuroblastoma
por: Gowda, Madhu, et al.
Publicado: (2013)

Crosstalk between metabolic reprogramming and epigenetics in cancer: updates on mechanisms and therapeutic opportunities
por: Ge, Tongxin, et al.
Publicado: (2022)

Review to Understand the Crosstalk between Immunotherapy and Tumor Metabolism
por: Pandey, Pratibha, et al.
Publicado: (2023)

The Crosstalk Between Tumor Cells and the Immune Microenvironment in Breast Cancer: Implications for Immunotherapy
por: Salemme, Vincenzo, et al.
Publicado: (2021)

Impacts and mechanisms of metabolic reprogramming of tumor microenvironment for immunotherapy in gastric cancer
por: Zhao, Lin, et al.
Publicado: (2022)

Metabolic reprogramming of T regulatory cells in the hypoxic tumor microenvironment
por: Sasidharan Nair, Varun, et al.
Publicado: (2021)

Crosstalk between Immune Checkpoint Modulators, Metabolic Reprogramming and Cellular Plasticity in Triple-Negative Breast Cancer
por: Poddar, Arpita, et al.
Publicado: (2022)

The adaptation model of immunity: Is the goal of central tolerance to eliminate defective T cells or self‐reactive T cells?
por: Manjili, Masoud H.
Publicado: (2022)

Tumor and immune reprogramming during immunotherapy in advanced renal cell carcinoma
por: Bi, Kevin, et al.
Publicado: (2021)

Editorial: The self-renewal and reprogramming of cancer stem cells and their crosstalk with the immune microenvironment
por: Li, Chong, et al.
Publicado: (2022)

Crosstalk between Gut Microbiota and Host Immunity: Impact on Inflammation and Immunotherapy
por: Campbell, Connor, et al.
Publicado: (2023)

Reprogramming Immune Cells for Enhanced Cancer Immunotherapy: Targets and Strategies
por: Dong, Yan, et al.
Publicado: (2021)

Harnessing Metabolic Reprogramming to Improve Cancer Immunotherapy
por: Yan, Liang, et al.
Publicado: (2021)

Metabolic reprogramming of the tumor immune microenvironment in ovarian cancer: A novel orientation for immunotherapy
por: Lin, Yi, et al.
Publicado: (2022)

Editorial: Understanding the crosstalk between immune cells and the tumor microenvironment in cancer and its implications for immunotherapy
por: Elemam, Noha Mousaad, et al.
Publicado: (2023)

Tumor Cell Dormancy: Threat or Opportunity in the Fight against Cancer
por: Jahanban-Esfahlan, Rana, et al.
Publicado: (2019)

Pancreatic cancer and fibrosis: Targeting metabolic reprogramming and crosstalk of cancer-associated fibroblasts in the tumor microenvironment
por: Li, Xin, et al.
Publicado: (2023)

Tumor Escape and Progression under Immune Pressure
por: Manjili, Masoud H., et al.
Publicado: (2012)

The crosstalking immune cells network creates a collective function beyond the function of each cellular constituent during the progression of hepatocellular carcinoma
por: Koelsch, Nicholas, et al.
Publicado: (2023)

Metabolic Reprogramming of Thyroid Cancer Cells and Crosstalk in Their Microenvironment
por: Bao, Lisha, et al.
Publicado: (2021)

Role of the tumor immune microenvironment in tumor immunotherapy
por: Zhou, Changsheng, et al.
Publicado: (2022)

Tyrosine kinase inhibitors reprogramming immunity in renal cell carcinoma: rethinking cancer immunotherapy
por: Aparicio, L. M. A., et al.
Publicado: (2017)

Insight into the Crosstalk between Photodynamic Therapy and Immunotherapy in Breast Cancer
por: Jin, Hongzhong, et al.
Publicado: (2023)

Role of Bladder Cancer Metabolic Reprogramming in the Effectiveness of Immunotherapy
por: Scholtes, Mathijs P., et al.
Publicado: (2021)

TLR-mediated metabolic reprogramming in the tumor microenvironment: potential novel strategies for cancer immunotherapy
por: Huang, Lan, et al.
Publicado: (2018)

Intratumoral pro-oxidants promote cancer immunotherapy by recruiting and reprogramming neutrophils to eliminate tumors
por: Ralph, Stephen John, et al.
Publicado: (2022)

Gr1(−/low)CD11b(−/low)MHCII(+) myeloid cells boost T cell anti‐tumor efficacy
por: Payne, Kyle K., et al.
Publicado: (2018)

Immune modulation of the tumor microenvironment for enhancing cancer immunotherapy
por: Devaud, Christel, et al.
Publicado: (2013)

Emerging roles of plasmacytoid dendritic cell crosstalk in tumor immunity
por: Yang, Leilei, et al.
Publicado: (2023)

Immunosuppressive mechanisms of oncofetal reprogramming in the tumor microenvironment: implications in immunotherapy response
por: Currenti, Jennifer, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_hs4jbmakobdjt0611vvk9loe0v